Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00257114 · ClinicalTrials.gov registry record · Phase 4
Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability
A Phase 4 study of Multiple Myeloma, sponsored by Millennium Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 1
- Study location
NCT00257114 is a Phase 4 study of Multiple Myeloma that has completed, run by Millennium Pharmaceuticals. The trial reports 1 study location across 1 state.
The verdict
NCT00257114, a Phase 4 study of Multiple Myeloma, has completed, sponsored by Millennium Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1
- Study location
Study Summary
Multiple myeloma represents the second most common hematological malignancy.VELCADE is a small molecule to treat human malignancies. Its anti-neoplastic effect invovles several distinct mechanisms including inhibition of cell growth. Patients who have relapsed or are refractory to therapy, the standard of care is now VELCADE based on the results of previous clinical trials.
Conditions Studied
Interventions
- DRUG bortezomib
Study Locations (1)
Maryland
- Sinai Hospital of Baltimore - Baltimore
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00257114
The ClinicalTrials.gov registry entry for NCT00257114 describes a study currently listed as completed, categorized as Phase 4. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Millennium Pharmaceuticals, which has 135 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which bortezomib is the first listed.
NCT00257114 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00257114 about?
NCT00257114 is a clinical study titled "Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability". Multiple myeloma represents the second most common hematological malignancy.VELCADE is a small molecule to treat human malignancies. Its anti-neoplastic effect invovles several distinct mechanisms including inhibition of cell growth. Patients who have relapsed or are refractory to therapy, the stand...
What is the current status of trial NCT00257114?
This trial is currently completed. It is a Phase 4 study.
What conditions does trial NCT00257114 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT00257114?
The interventions under investigation include: bortezomib (DRUG).
Who is sponsoring clinical trial NCT00257114?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00257114 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
RECRUITING · Phase 4
-
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
RECRUITING · Phase 4
-
Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial
RECRUITING · Phase 4
-
A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)
ACTIVE NOT RECRUITING · Phase 4
-
Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma
COMPLETED · Phase 4
-
Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Participants
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.